A Study to Assess the Safety and Tolerability of PF-07055480/Giroctocogene Fitelparvovec Gene Therapy in Adults With Severe Hemophilia A
A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 [PF-07055480] [Recombinant AAV2/6 Human Factor 8 Gene Therapy] in Adult Subjects With Severe Hemophilia A
Category & Conditions: Rare Diseases
Medicine: giroctocogene fitelparvovec (PF-07055480)
ClinicalTrials.gov Identifier (NCT): NCT03061201
Protocol ID: C3731001
Open Plain Language Summary Result:
Click here